Effects of Inspiratory Muscle Training in Patients With Parkinson's Disease

June 17, 2020 updated by: Bezmialem Vakif University

Effects of Inspiratory Muscle Training on Postural Stability, Mobility, Activities of Daily Living, Quality of Life and Respiratory Function in Patients With Parkinson's Disease

In this study investigators will examine the effects of inspiratory muscle training and balance training in patients with Parkinson's Disease

Study Overview

Detailed Description

Parkinson's Disease (PD) is the most common type of Parkinsonism and mainly due to degeneration of basal ganglions and substantia nigra occurs. Balance disorders are one of the common problems in patients with Parkinson's disease. These balance disorders; loss of postural reflexes, insufficiency in postural adjustments, rigidity in the trunk and extremities, and many disorders such as akinesia. Because of balance disorders in patients with PD, increase in addiction to daily life activities, causes physical disability. In the case of PD pulmonary problems may be the leading cause of mortality and mortality. Respiratory symptoms in these patients cause problems in weakness, swallowing, coughing, voice and speech functions. When the investigators look at the current literature, the effect of balance and respiration on Parkinson's patients is found to be seperately but their effect on each other is not sufficiently emphasized. For this reason, the researchers' aim to investigate balance and postural control in patients with Parkinson's disease and to increase the strength of respiratory muscles and to improve balance and postural control.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Istanbul, Turkey
        • Bezmialem Vakif University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years to 85 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosed with Parkinson'S Disease
  • Ages between 60 and 85 years
  • Grades 1 to 3 according to Modified Hoehn-Yahr Scale

Exclusion Criteria:

  • Lung surgery or diagnosed lung disease history
  • Dementia
  • Having a orthopedic disorder which may affect balance and/or mobility
  • Severe dyskinesia and cognition problems

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Control Group
The control group will be receive 45 minutes training sessions 3 times a week for 8 weeks; 2 days a week for home based balance training and 1 day for supervisory training with Bio-Dex Balance-System ®.
Respiratory muscle strengths will evalueted with inspiratory and expiratory mouth pressure devices.
Balance training will provide with Biodex® Balance Training System
ACTIVE_COMPARATOR: Training Group
The training group will receive inspiratory muscle training; 15 minutes sessions 5 times a week for 8 weeks in addion to balance training same as control.
Respiratory muscle strengths will evalueted with inspiratory and expiratory mouth pressure devices.
Balance training will provide with Biodex® Balance Training System
15 minutes twice a day, 5 times a week for 8 week with Threshold IMT device

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Inspiratory Muscle Strength
Time Frame: Change from baselines to final evaluation at 8th weeks
Maximal inspiratory pressure (MIP) is the most widely used measure of respiratory muscle strength in patients with suspected respiratory muscle weakness. It is determined by measuring upper airway pressure (mouth for outpatients and trachea for intubated or tracheostomized patients) during a maximal voluntary inspiratory effort. The measured pressure is a composite of the pressure generated by the inspiratory muscles and the elastic recoil pressure of the lungs and chest wall.
Change from baselines to final evaluation at 8th weeks
Respiratory Function- Forced Vital Capasity (FVC)
Time Frame: Change from baselines to final evaluation at 8th weeks
Forced vital capacity (FVC) is the total amount of air exhaled during the FEV test. FVC can also help doctors assess the progression of lung disease and evaluate the effectiveness of treatment.
Change from baselines to final evaluation at 8th weeks
Respiratory Function- Forced Expiratory Volume in 1 second
Time Frame: Change from baselines to final evaluation at 8th weeks

Forced expiratory volume (FEV) measures how much air a person can exhale during a forced breath. Forced expiratory volume and forced vital capacity are lung function tests that are measured during spirometry. Forced expiratory volume is the most important measurement of lung function. It is used to:

Diagnose obstructive lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). A person who has asthma or COPD has a lower FEV1 result than a healthy person.

See how well medicines used to improve breathing are working. Check if lung disease is getting worse. Decreases in the FEV1 value may mean the lung disease is getting worse.

Change from baselines to final evaluation at 8th weeks
Respiratory Function- Peak Expiratory Flow
Time Frame: Change from baselines to final evaluation at 8th weeks
The peak expiratory flow (PEF), also called peak expiratory flow rate (PEFR), is a person's maximum speed of expiration, as measured with a peak flow meter, a small, hand-held device used to monitor a person's ability to breathe out air.
Change from baselines to final evaluation at 8th weeks
Postural Control and Balance
Time Frame: Change from baselines to final evaluation at 8th weeks
Biodex Balance System evaluations
Change from baselines to final evaluation at 8th weeks
Parkinson's Status- Unified Parkinson's Disease Rating Scale
Time Frame: Change from baselines to final evaluation at 8th weeks
The UPDRS scale refers to Unified Parkinson Disease Rating Scale, and it is a rating tool used to gauge the course of Parkinson's disease in patients. The UPDRS scale includes series of ratings for typical Parkinson's symptoms that cover all of the movement hindrances of Parkinson's disease. The UPDRS scale consists of the following five segments: 1) Mentation, Behavior, and Mood, 2) ADL, 3) Motor sections, 4) Modified Hoehn and Yahr Scale, and 5) Schwab and England ADL scale. Each answer to the scale is evaluated by a medical professional that specializes in Parkinson's disease during patient interviews.
Change from baselines to final evaluation at 8th weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mobility Status- Rivermead mobility index
Time Frame: Change from baselines to final evaluation at 8th weeks

The Rivermead Mobility Index assesses functional mobility in gait, balance and transfers. The Rivermead Mobility Index is appropriate for a range of disabilities that include anything from being bedridden to being able to run 15 items:

14-self-reported items

1 direct observation item Items progress in difficulty Items are coded as either 0 or 1, depending on whether the patient can complete the task according to specific instructions Items receive a score of 0 for a "No" response and 1 for a "Yes" response Total scores are determined by summing the points for all items A maximum of 15 points is possible; higher scores indicate better mobility performance A score of "0" indicates an inability to perform any of the activities on the measure

Change from baselines to final evaluation at 8th weeks
Quality of Life Parameter-Nottingham Health Profile
Time Frame: Change from baselines to final evaluation at 8th weeks

The Nottingham Health Profile is intended for primary health care, to provide a brief indication of a patient's perceived emotional, social and physical health problems. Breakdown of questionaire

(1) Part I: 38 questions in 6 subareas, with each question assigned a weighted value; the sum of all weighted values in a given subarea adds up to 100

  • energy level (EL): 3
  • pain (P): 8
  • emotional reaction (ER): 9
  • sleep (S): 5
  • social isolation (SI): 5
  • physical abilities (PA): 8
Change from baselines to final evaluation at 8th weeks
Activities of Daily Living-Barthel
Time Frame: Change from baselines to final evaluation at 8th weeks
The Barthel Scale/Index (BI) is an ordinal scale used to measure performance in activities of daily living (ADL). Ten variables describing ADL and mobility are scored, a higher number being a reflection of greater ability to function independently following hospital discharge.Time taken and physical assistance required to perform each item are used in determining the assigned value of each item. The Barthel Index measures the degree of assistance required by an individual on 10 items of mobility and self care ADL.
Change from baselines to final evaluation at 8th weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Hülya N Gürses, Prof, Bezmialem Vakif University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

May 4, 2018

Primary Completion (ACTUAL)

January 1, 2020

Study Completion (ACTUAL)

January 15, 2020

Study Registration Dates

First Submitted

August 5, 2019

First Submitted That Met QC Criteria

January 13, 2020

First Posted (ACTUAL)

January 14, 2020

Study Record Updates

Last Update Posted (ACTUAL)

June 18, 2020

Last Update Submitted That Met QC Criteria

June 17, 2020

Last Verified

June 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

Clinical Trials on Respiratory Muscle Strength

3
Subscribe